Chr del(11)(q22.3)

News alerts, weekly reports and conference planners

Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	ibrutinib + rituximab Sensitive: B - Late Trials ibrutinib + rituximab Sensitive : B	ibrutinib + rituximab Sensitive: B - Late Trials ibrutinib + rituximab Sensitive : B
Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B
Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: C3 – Early Trials alemtuzumab Sensitive : C3	alemtuzumab Sensitive: C3 – Early Trials alemtuzumab Sensitive : C3
Chr del(11)(q22.3)	Small Lymphocytic Lymphoma	Chr del(11)(q22.3)	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: C3 – Early Trials acalabrutinib Sensitive : C3	acalabrutinib Sensitive: C3 – Early Trials acalabrutinib Sensitive : C3

Associations